Democratizing Data at Novartis Through Clinical Trial Data Access: Lessons Learned from Building the Data42 Program | Kisaco Research

Democratizing Data at Novartis Through Clinical Trial Data Access: Lessons Learned from Building the Data42 Program

  • Addressing the technical, cultural and policy hurdles that traditionally impede the broad access and usage of clinical trial data
  • Layout a blueprint for companies to accelerate their progress in a patient-first manner
  • Developing a framework to automatically approval clinical trial data requests
  • Exploring the impact this has had on Novartis and the broader industry
Speaker(s): 

Author:

Gabriel Eichler

Vice President of Data, Data 42
Novartis

Ech

... read more

Gabriel Eichler

Vice President of Data, Data 42
Novartis

Ech